These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 32450562)

  • 1. Real-Life Comparison of Different Anti-TNF Biologic Therapies for Ulcerative Colitis Treatment: A Retrospective Cohort Study.
    Barberio B; Zingone F; Frazzoni L; D'Incà R; Maccarone MC; Ghisa M; Massimi D; Lorenzon G; Savarino EV
    Dig Dis; 2021; 39(1):16-24. PubMed ID: 32450562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study.
    Barberio B; Zingone F; D'Incà R; Rovigo L; Bertani L; Bodini G; Ghisa M; Gubbiotti A; Massimi D; Lorenzon G; Savarino EV
    Clin Transl Gastroenterol; 2020 May; 11(5):e00177. PubMed ID: 32677808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
    Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
    Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study.
    Viola A; Pugliese D; Renna S; Furfaro F; Caprioli F; D'Incà R; Bossa F; Mazza S; Costantino G; Fantini MC; Fiorino G; Alibrandi A; Orlando A; Armuzzi A; Fries W
    Dig Liver Dis; 2019 Apr; 51(4):510-515. PubMed ID: 30472389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis.
    Macaluso FS; Ventimiglia M; Fries W; Viola A; Cappello M; Scrivo B; Magnano A; Pluchino D; Camilleri S; Garufi S; Mitri RD; Mocciaro F; Magrì G; Ferracane C; Citrano M; Graziano F; Bertolami C; Renna S; Orlando R; Rizzuto G; Cottone M; Orlando A;
    Dig Liver Dis; 2020 Dec; 52(12):1461-1466. PubMed ID: 32601033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of biologics in pediatric inflammatory boweldisease: Real-life data from the Sicilian Network.
    Romeo AC; Ventimiglia M; Dipasquale V; Orlando A; Citrano M; Pellegrino S; Accomando S; Cottone M; Romano C
    Clin Res Hepatol Gastroenterol; 2020 Apr; 44(2):223-229. PubMed ID: 31204314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice.
    Marutani Y; Mizoshita T; Sugiyama T; Togawa S; Katano T; Yamada T; Hirata Y; Kimura Y; Miyaki T; Inoue Y; Suzuki E; Sasaki M; Kataoka H
    Indian J Gastroenterol; 2020 Dec; 39(6):565-575. PubMed ID: 33106991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of Treatment Guidelines for Ulcerative Colitis: Role of Biologics].
    Bae JH; Yang DH
    Korean J Gastroenterol; 2018 Apr; 71(4):192-195. PubMed ID: 29684967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study.
    Hupé M; Rivière P; Nancey S; Roblin X; Altwegg R; Filippi J; Fumery M; Bouguen G; Peyrin-Biroulet L; Bourreille A; Caillo L; Simon M; Goutorbe F; Laharie D
    Aliment Pharmacol Ther; 2020 May; 51(9):852-860. PubMed ID: 32201971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB).
    Sassaki LY; Magro DO; Saad-Hossne R; Baima JP; Flores C; Correia LM; Celani LMS; De Abreu Ferrari ML; Zacharias P; Feitosa MR; Dos Santos CHM; De Freitas Lins Neto MA; Quaresma AB; De Lima Junior SF; De Vasconcelos GBS; Cassol OS; Dos Santos Pinto A; Kurachi G; Goncalves Filho FA; Gasparini RG; Furlan TK; Catapani WR; Coy CSR; De Souza Menegassi V; Colombo MM; Fróes RSB; Teixeira FV; Moraes AC; Santana GO; Parente JML; Vilela EG; Queiroz NSF; Kotze PG;
    BMC Gastroenterol; 2022 May; 22(1):268. PubMed ID: 35644668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource.
    Kapizioni C; Desoki R; Lam D; Balendran K; Al-Sulais E; Subramanian S; Rimmer JE; De La Revilla Negro J; Pavey H; Pele L; Brooks J; Moran GW; Irving PM; Limdi JK; Lamb CA; ; Parkes M; Raine T
    J Crohns Colitis; 2024 Jun; 18(6):790-800. PubMed ID: 38041850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment persistence and maintenance dose titration among ulcerative colitis patients on biologics: a pooled study of three United States claim databases.
    Sah J; Teeple A; Muser E; Gutierrez C; Dassopoulos T
    Curr Med Res Opin; 2022 Jul; 38(7):1093-1101. PubMed ID: 35475385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of infliximab biosimilar CT-P13 in treating ulcerative colitis: a real‑life experience in IBD primary centers.
    Tursi A; Allegretta L; Chiri S; Della Valle N; Elisei W; Forti G; Lorenzetti R; Mocci G; Penna A; Pranzo G; Ricciardelli C; Picchio M
    Minerva Gastroenterol Dietol; 2017 Dec; 63(4):313-318. PubMed ID: 28293938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.
    Iborra M; Pérez-Gisbert J; Bosca-Watts MM; López-García A; García-Sánchez V; López-Sanromán A; Hinojosa E; Márquez L; García-López S; Chaparro M; Aceituno M; Calafat M; Guardiola J; Belloc B; Ber Y; Bujanda L; Beltrán B; Rodríguez-Gutiérrez C; Barrio J; Cabriada JL; Rivero M; Camargo R; van Domselaar M; Villoria A; Schuterman HS; Hervás D; Nos P;
    J Gastroenterol; 2017 Jul; 52(7):788-799. PubMed ID: 27722996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort.
    Bossuyt P; Baert F; D'Heygere F; Nakad A; Reenaers C; Fontaine F; Franchimont D; Dewit O; Van Hootegem P; Vanden Branden S; Lambrecht G; Ferrante M;
    Inflamm Bowel Dis; 2019 Jan; 25(1):156-162. PubMed ID: 29920582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Infliximab Biosimilar Versus Originator in a Pediatric United Kingdom Inflammatory Bowel Disease Induction Cohort.
    Chanchlani N; Mortier K; Williams LJ; Muhammed R; Auth MKH; Cosgrove M; Fagbemi A; Fell J; Chong S; Zamvar V; Hyer W; Bisset WM; Morris MA; Rodrigues A; Mitton SG; Bunn S; Beattie RM; Willmott A; Wilson DC; Russell RK
    J Pediatr Gastroenterol Nutr; 2018 Oct; 67(4):513-519. PubMed ID: 29697550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis.
    Kumar P; Vuyyuru SK; Kante B; Kedia S; Sahu P; Ranjan MK; Mundhra S; Golla R; Kumar M; Virmani S; Gupta A; Yadav N; Makharia G; Ahuja V
    Indian J Gastroenterol; 2022 Oct; 41(5):446-455. PubMed ID: 36378484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Golimumab for moderately to severely active ulcerative colitis.
    Kedia S; Ahuja V; Makharia GK
    Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis.
    Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
    Aliment Pharmacol Ther; 2016 May; 43(9):994-1003. PubMed ID: 26991059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.